P atients with atrial fibrillation (AF) are increasingly treated with oral anticoagulation (OAC), which has been shown to reduce the risk of stroke/systemic embolism and all-cause mortality, in comparison with control.
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the optimal treatment option is unknown and requires balancing the competing risk of ischemic stroke and recurrent ICH in AF patients. Using Danish nationwide registries cohort, we investigated the hypothesis that, among AF patients presenting with an ICH, restarting OAC was associated with a lower risk of recurrent stroke and mortality, but with a small increase in major bleeding (particularly ICH) in comparison with not restarting.
Methods
We used the civil registration number assigned to all Danish residents to link 3 nationwide databases [14] [15] [16] as follows: (1) discharge diagnoses classified by the International Classification of Diseases, 10th Revision (ICD-10), admission and discharge dates were obtained from the Danish National Patient Registry; (2) dispensed prescriptions identified by the Anatomic Therapeutic Chemical classification code, date of purchase, package size, and volume of the medication since 1994 were obtained from the Danish National Prescription Registry; and (3) information on age, sex, date of birth, emigration, and vital status were attained from the Danish Civil Registration System. Retrospective studies do not require ethical approval in Denmark.
Study Population
All Danish citizens with an incident nonvalvular AF diagnosis between January 1997 and December 2013 were identified. Patients with a subsequent incident ICH (ICD-10: I60-I62, S063C, S064-S066) requiring admission to a hospital were included. Exclusion criteria were valvular AF defined as the presence of mitral stenosis or mechanical heart valve (ICD-10: I05 and Z952-Z954). Patients with ICH or complications from ICH (ICD-10: I690-692) before their AF diagnosis were also excluded. We further required patients to be in OAC treatment defined as a claimed VKA or NOAC prescription within 6 months before the ICH event. This was done to support the assumption that included patients were indeed in OAC treatment at the time of the incident ICH event. Patients were followed in the National Patient Registry after a quarantine period defined as 6 weeks after hospital discharge. This period was chosen to ensure that events could reasonably be attributed to treatment regimens rather than inadequate correction of the initial coagulation deficit, that is, reversal of the incident ICH (and adjacent) event. 9, [17] [18] [19] [20] Further, the use of a relatively long quarantine period can reduce confounding by indication, because those patients initially deemed at a very high risk of recurrent ICH would probably not be advised to resume anticoagulation within this period (eg, patients with lobar hemorrhage 21 ).
Exposure to Antithrombotic Treatment
We identified all prescriptions of antiplatelet therapy (aspirin/thienopyridines) and OAC treatment (VKA/NOAC) to classify patients by treatment regimens as no antithrombotic treatment, antiplatelet therapy, or OAC treatment. The following Anatomic Therapeutic Chemical codes were used to account for OAC treatment: B01AA (coumarin derivatives), B01AE07 (dabigatran etexilate), and B01AF01-02 (rivaroxaban and apixaban). For antiplatelet therapy, the following Anatomic Therapeutic Chemical codes were used: B01AC06 (aspirin) and B01AC04, B01AC22, and B01AC24 (thienopyridines). When discharged from the hospital, all included patients were initially assigned to no antithrombotic treatment, and, if antithrombotic therapy was reinitiated, to either antiplatelet therapy or OAC treatment categories, whichever prescription was claimed first (Figure 1 ). Treatment exposure was consequently considered as a time-dependent covariate.
Outcome Measures
The primary analysis plan used the principal outcomes of ischemic stroke/systemic embolism (SE), all-cause mortality and recurrent ICH. Given the severity of the studied outcomes, we only considered events if the patient was admitted to the hospital 22 ; hence, we did not consider ambulatory diagnosis. In addition, emergency department-coded diagnoses were not included in this study because of poor validity. 23 The primary study end point was a combined end point of ischemic stroke/ SE (ICD-10 diagnosis: I63, I64, I74) and all-cause mortality, given the positive impact of OAC on stroke and mortality 1 and recognizing that, in registry data, some deaths may be due to undiagnosed stroke/SE because neither postmortems nor cerebral imaging are mandated.
Secondary analyses were performed for ischemic stroke/SE, for recurrent ICH, for major extracranial bleeding (ICD-10: D62, J942,  H113, H356, H431, N02, N95, R04, R31, R58, K250, by guest on April 21, 2017 http://circ.ahajournals.org/ Downloaded from K280, K290), and for all-cause mortality. If, in the primary analysis, antithrombotic therapy did show benefit versus being left untreated (commonly seen in practice post-ICH 5, 24 ), a secondary analysis calculating net clinical benefit (NCB) of resuming antithrombotic therapy (versus no antithrombotic therapy) was calculated by the methods previously proposed balancing ischemic stroke reduction versus the increased risk of ICH. 25 NCB with 95% confidence intervals (CIs) was based on rate differences and standard errors estimated obtained by using Poisson regression. We applied a weight of 1 for ischemic stroke/SE and all-cause mortality and a weight of 1.5 for recurrent ICH as proposed by Singer et al. 25 Accompanying the NCB analysis, we also investigated the event rate for the composite outcome of ischemic stroke/SE/major bleeding (including recurrent ICH). In addition, we performed a sensitivity analysis by altering the quarantine period when investigating the outcome of ischemic stroke/SE and all-cause mortality and recurrent ICH. This was done to assess if the choice of quarantine period would differ from the main analysis (using a 6-week quarantine period).
Patient Characteristics and Concomitant Medication
Comorbidities were ascertained from preceding hospital diagnoses until discharge from the incident ICH event. Filled prescriptions 1 year before baseline defined other concomitant medication. The cardiovascular comorbidity and risk of stroke at baseline were assessed by the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age >75 years, diabetes mellitus, stroke, vascular disease, age 65-75 years, and female sex) score. 26, 27 We calculated the HAS-BLED (hypertension, abnormal renal/liver function, stroke/thromboembolism, bleeding history, labile international normalized ratio [not included], elderly [age >65 years], drug consumption/alcohol excess [aspirin was not included owing to status of exposure]) score for each patient to assess the bleeding risk. 28 Table I in the online-only Data Supplement provides a detailed description on outcomes and concomitant medication.
Statistical Analyses
Patients were followed until the occurrence of the following censoring events: a claimed prescription indicating dual-treatment regimen (both OAC and antiplatelet treatment), occurrence of a study end point, emigration, end of study, or death, whichever came first ( Figure 1 ). For outcome analyses, events were ascertained from 6 weeks after hospital discharge. Exposure to antithrombotic treatment was regarded as 2 time-dependent covariates (1 for OAC treatment and 1 for antiplatelet therapy) with 1 irreversible binary transition (from 0 to 1). We calculated crude events rates at 1 and 5 years by dividing the number of events occurring during followup with the person-years of follow-up for each treatment group. To compare event rates associated under antithrombotic treatment regimens versus no antithrombotic treatment, crude and adjusted hazard ratios (HRs) were estimated by means of the Cox proportional hazards model. The adjusted analyses included information on age (restricted cubic spline); sex (binary); year of inclusion (categories of 5 years); time since last claimed OAC prescription before the incident ICH event (restricted cubic spline); and categories of the CHA 2 DS 2 -VASc score (0, 1, ≥2 points) and HAS-BLED score (0-2, ≥3 points). We additionally used information on ischemic stroke/SE and recurrent ICH events during the quarantine period (binary). The reasoning behind this adjustment was that such events could affect the choice of antithrombotic treatment before the observation time commenced. In addition, a sensitivity analysis was conducted by excluding patients who experienced an event within the quarantine period.
To depict the overall 5-year prognosis, we obtained the KaplanMeier estimates. The patients were stratified according to purchase of OAC (respectively, antiplatelet drugs) during the quarantine period (6-week landmark), and patients with dual-treatment exposure were excluded (prescription claim of both an OAC and antiplatelet drug).
To assess the impact of allowing more time for claiming a prescription used for treatment regimen allocation, we made a sensitivity analysis by setting the landmark to 180 days.
We used a 2-sided P value threshold of P<0.05 for statistical significance. Statistical analyses were performed by using SAS 9.3 (SAS Institute) and Stata version 13 (StataCorp LP).
Results
A total of 6138 patients with nonvalvular AF who experienced an incident ICH were identified in the period from January 1, 1997, to December 31, 2013 . Within the quarantine period of 6 weeks, 1652 patients died, whereas 32 patients were excluded because of insufficient follow-up time (ie, encountered study end within the quarantine period). The study population comprised 1752 patients who fulfilled the inclusion criteria by having claimed an OAC prescription within 6 months of the incident ICH event and were still alive after the 6-week quarantine period; see Figure 1 for flowchart and Table 1 for study population characteristics. The proportion of patients included in the analysis with previous OAC treatment receiving VKA was 65%, and proportion of patients receiving the combination of VKA and antiplatelet therapy was 33%. With NOACs, the proportion was 2%, whereas <1% received combination therapy with a NOAC and antiplatelet therapy. The mean CHA 2 DS 2 -VASc score was 3.9 and the mean HAS-BLED score was 3.2, indicating a study population at high risk of both thromboembolic events, and a high risk of bleeding, as well.
Of the patients who resumed OAC treatment (n=621), 77% claimed an OAC prescription within first 3 months after hospital discharge, with an overall median days of 34 to first claimed prescription. For those who received antiplatelet therapy (n=759), 65% claimed a prescription within first 3 months, with an overall median time of 24 days. During the first year of follow-up, 218 patients either shifted treatment or initiated dual-antithrombotic treatment and were accordingly censored.
Stroke/SE and All-Cause Mortality
A total of 39 patients had an ischemic stroke/SE during the quarantine period of 6 weeks; of those, 5 patients had already claimed an OAC prescription, whereas 11 patients received antiplatelet therapy. The overall event rates (expressed as per 100 person-years) using 1 year of follow-up of the combined end point of ischemic stroke/SE and all-cause mortality in OAC treated versus no antithrombotic treatment were 13.6 versus 27.3 (adjusted HR, 0.55; 95% CI, 0.39-0.78), and 25.7 for antiplatelet therapy (adjusted HR, 0.87; 95% CI, 0.67-1.14; Table 2 and Figure 2 ). The event rates for ischemic stroke/SE in OAC treated versus no antithrombotic treatment were 5.3 versus 10.4 at 1 year of follow-up (adjusted HR, 0.59; 95% CI, 0.33-1.03), and 10.3 for antiplatelet therapy (adjusted HR, 0.98; 95% CI, 0.65-1.49). For all-cause mortality, the event rates were 9.7 for OAC treated versus 19.1 for no antithrombotic treatment (adjusted HR, 0.55; 95% CI, 0.37-0.82), and 19.5 for antiplatelet therapy (adjusted HR, 0.90; 95% CI, 0.67-1.21). The crude and adjusted analyses contrasting treatment regimens were comparable. Table II in Figure 3 depicts the Kaplan-Meier estimates of 5-year survival in patients who resumed OAC treatment, respectively, received antiplatelet therapy, and those who did not. A landmark at 6 weeks (quarantine period) was used to allocate patient treatment regimens: 1089 patients were assigned to the no antithrombotic treatment group, 303 were assigned to OAC treatment, and 360 were assigned to the antiplatelet therapy group.
Recurrent ICH and Major Bleeding
Of a total of 298 recurrent ICH events, 177 events (60%) occurred during the quarantine period, that is, before the observation time commenced; of these, 27 patients had claimed an OAC prescription, whereas 35 patients received antiplatelet therapy. For recurrent ICH using 1 year of followup, the rates were 8.0 for OAC treated versus 8.6 for no antithrombotic treatment adjusted HR, 0.91; 95% CI, 0.56-1.49), and 5.3 for antiplatelet therapy (adjusted HR, 0.60; 95% CI, 0.37-1.03). The event rates of major extracranial bleedings in OAC treated versus no antithrombotic treatment were 1.5 versus 1.5 (adjusted HR, 0.92; 95% CI, 0.30-2.76), and 2.6 for antiplatelet therapy (adjusted HR, 1.57; 95% CI, 0.62-3.92; Table 2 and Figure 2) . The crude and adjusted analyses contrasting treatment regimens for bleeding outcomes were broadly comparable.
Secondary Analysis
The 1-year event rate for the combined end point of ischemic stroke/SE/major bleeding (including ICH) was 27.4 for no antithrombotic treatment, 17.1 for OAC treatment, and 23.2 for patients receiving antiplatelet therapy. Because OAC did demonstrate a significant reduction in stroke/SE and all-cause mortality, we calculated the 1-year NCB of OAC or antiplatelet therapy use versus no antithrombotic treatment. The NCB was calculated as a weighted sum of rate differences for the combined end point of ischemic stroke/SE and all-cause mortality and recurrent ICH. The NCB for OAC versus no antithrombotic treatment was 14.6 (95% CI, 6.4-22.8), whereas the NCB was nonsignificant for antiplatelet therapy versus no antithrombotic treatment, 6.5 (95% CI, -2.1 to 15.2).
Sensitivity Analysis
A sensitivity analysis of the Kaplan-Meier estimates stratified according to treatment regimens using a landmark at 180 days (relative to hospital discharge) for treatment allocation is shown in Figure I in the online-only Data Supplement. A total of 1541 patients contributed to this analysis, and the survival curves were similar to those presented in Figure 3 supporting OAC treatment.
Altering the quarantine period ranging from 2 to 10 weeks essentially did not affect the primary outcome of ischemic stroke/SE and all-cause mortality (see Figure 4) . The total number of patients contributing to these analyses was 1838, 1793, 1752, 1732, and 1712 using the 2-, 4-, 6-, 8-, and 10-week quarantine period, respectively. Contrary, the outcome of recurrent ICH was somewhat affected by the choice of quarantine period. The HR contrasting OAC treatment versus no treatment ranged from 0.41 (95% CI, 0.27-0.63) for the2-week quarantine period, to 1.42 (95% CI, 0.83-2.43) when applying a 10-week quarantine period. In general, the results obtained on HR contrasting treatment regimens were not affected by excluding those patients who experienced an event (ischemic stroke/SE and recurrent ICH) during the quarantine period. However, the outcome of recurrent ICH for patients on OAC treatment displayed an adjusted HR of 1.30 (95% CI, 0.75-2.27).
Discussion
In this analysis, we found that AF patients who experience an ICH are very high risk of ischemic stroke and mortality if they are not on antithrombotic therapy. Patients who were not on OAC treatment had the worst adverse outcomes, which were similar to rates seen with antiplatelet therapy. Importantly, OAC treatment was associated with a significant reduction in subsequent ischemic stroke and all-cause mortality.
ICH is the most feared complication of OAC treatment; it is associated with a high mortality and morbidity, and survivors often have greater disability. Patients with ICH were not included in randomized trials, and it is an open problem to decide the best time window to reintroduce OAC treatment following a presentation with ICH. Our analysis does not define the best time window to reintroduce OAC but makes the observation in this nonrandomized observational cohort that OAC use was associated with significantly lower risks of ischemic stroke and all-cause mortality.
The risk of recurrent ICH was also high in our patients, and was equally high among non-OAC-treated or OACtreated patients, whereas the risk of recurrent ICH slightly lower in patients who received antiplatelet therapy. Factors contributing to recurrent ICH have been reported in different 8, 9, 29, 30 and include increasing age, concomitant use of aspirin or nonsteroidal anti-inflammatory drugs, uncontrolled hypertension, etc. As previously shown in clinical trials and nationwide registries, the HAS-BLED score is the only bleeding risk score that is predictive of major bleeding risk and reflects the risk factors commonly associated with this complication. 4, 28, 31 Common practice is to consider no antithrombotic treatment or antiplatelet therapy (commonly aspirin) as a safer alternative than OAC following a presentation with ICH, and the American Heart Association/American Stroke Association guideline provides a class IIb recommendation of antiplatelet therapy after all types of ICH (and "OAC might be considered after nonlobar ICH"). 32 Our data do not support such an approach with a higher ischemic stroke and substantially higher mortality, with a nonsignificant reduction in recurrent ICH among antiplatelet therapy users. Even in randomized trials of stroke prevention in AF, the risk of ICH (and major bleeding) is no different between OAC-and aspirin-treated patients, especially in the elderly. 33, 34 Also, our secondary analyses show that the NCB for OAC treatment was positive, versus no antithrombotic therapy, whereas the NCB for aspirin versus no antithrombotic therapy was nonsignificant.
The present study has clinical implications, in that it supports OAC reintroduction as soon as clinically feasible. However, given the nonrandomized design and data limitations, caution on overinterpretation of the results is warranted; we were not able to distinguish between the severities of risk factors, which may reflect physician's choices of OAC resumption. Potentially correctable risk factors for ICH should be addressed including the assessment of the HAS-BLED score, correction of uncontrolled high blood pressure, concomitant use of aspirin or nonsteroidal anti-inflammatory drugs, etc. ICH can sometimes be related to trauma or a vascular anomaly, and, for the latter, liaison with a neurosurgical service is important.
Limitations
We did not have data on international normalized ratio values; hence, there is no estimate of OAC intensity; and we also recognize the importance of the quality of anticoagulation control, as reflected by time in therapeutic range. 35, 36 VKAs are associated with a relatively higher rate of ICH than NOACs, but the latter were only used in a minority of patients in our study. We also did not have any cerebral imaging data to distinguish the subtypes of ICH, but our principal hypothesis pertained to the simple question of whether or not restarting OAC after ICH was associated with a beneficial effect on stroke and mortality in patients with AF. Indeed, the presence of microbleeds is an important risk for ICH, and many stroke physicians would be cautious about restarting OAC in a patient with widespread cerebral microbleeds. There is a potential risk of misclassification of recurrent ICH events owing to routine procedures after hospital discharge: patients are likely to be readmitted to a hospital for a follow-up computerized tomography scan examining rebleedings. This readmission could inherit the coding from the incident ICH with no evidence of any recurrent bleeding. This conjecture was supported by the sensitivity analyses of altering the quarantine period, and also by excluding those patients who experienced an event during the quarantine period. On the other hand, with the lack of information on the cause of death, the number of ischemic events or recurrent ICH could be underestimated if they carried a terminal outcome. Our analysis on treatment initiation was performed using an assumption of adherence to treatment (unless changed from OAC to antiplatelet therapy or vice versa), recognizing the limitations of a real-world cohort design, where patients could change from treatment (and doses) to no treatment over time. We also only included patients with an index hospitalization for AF, and documented ICH; thus, confounding by indication and selection bias could be evident, and our results may not be generalizable to the general nonhospitalized AF population. Nonetheless, most patients with an ICH would require hospitalization, and AF-related hospitalizations are common (and increasing); thus, our analysis would reflect the likely burden of AF patients in healthcare systems. Although this was a nationwide study, the ethnic background of the Danish population is presumably white, and thus the obtained results might not generalize to all ethnic groups. 39 In conclusion, AF patients who experience an ICH are at very high risk of ischemic stroke and death, and our data indicate positive clinical benefit from anticoagulant treatment. OAC treatment resulted in a significant reduction in subsequent ischemic stroke and all-cause mortality. As such, this study supports OAC reintroduction post-ICH, but, owing to the risk of bias by unmeasured confounding, future randomized, controlled trials investigating the resumption of OAC treatment post-ICH are encouraged to provide further evidence to guide clinical practice.
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